Company News

Revive Therapeutics Files Business Acquisition Report

Revive Therapeutics Ltd. (" Revive " or the " Company ") (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR) pursuant to National Instrument 51-102 Continuous Disclosure Obligations in connection with its acquisition of Psilocin Pharma Corp. on March 5, 2020.‎ The BAR has been filed as a result of a review conducted by staff at the Ontario Securities Commission in connection with the Company's recently filed preliminary short form prospectus dated January 26, 2021.

For more information, please contact :

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

Latest Press Releases

Related News